These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Mascola JR; Stiegler G; VanCott TC; Katinger H; Carpenter CB; Hanson CE; Beary H; Hayes D; Frankel SS; Birx DL; Lewis MG Nat Med; 2000 Feb; 6(2):207-10. PubMed ID: 10655111 [TBL] [Abstract][Full Text] [Related]
45. Comparison of immunity generated by nucleic acid-, MF59-, and ISCOM-formulated human immunodeficiency virus type 1 vaccines in Rhesus macaques: evidence for viral clearance. Verschoor EJ; Mooij P; Oostermeijer H; van der Kolk M; ten Haaft P; Verstrepen B; Sun Y; Morein B; Akerblom L; Fuller DH; Barnett SW; Heeney JL J Virol; 1999 Apr; 73(4):3292-300. PubMed ID: 10074183 [TBL] [Abstract][Full Text] [Related]
46. Immunogenicity and efficacy of DNA/MVA HIV vaccines in rhesus macaque models. Chea LS; Amara RR Expert Rev Vaccines; 2017 Oct; 16(10):973-985. PubMed ID: 28838267 [TBL] [Abstract][Full Text] [Related]
47. Analysis of Complement-Mediated Lysis of Simian Immunodeficiency Virus (SIV) and SIV-Infected Cells Reveals Sex Differences in Vaccine-Induced Immune Responses in Rhesus Macaques. Miller-Novak LK; Das J; Musich TA; Demberg T; Weiner JA; Venzon DJ; Mohanram V; Vargas-Inchaustegui DA; Tuero I; Ackerman ME; Alter G; Robert-Guroff M J Virol; 2018 Oct; 92(19):. PubMed ID: 30021899 [TBL] [Abstract][Full Text] [Related]
48. Multi-envelope HIV-1 vaccine devoid of SIV components controls disease in macaques challenged with heterologous pathogenic SHIV. Zhan X; Martin LN; Slobod KS; Coleclough C; Lockey TD; Brown SA; Stambas J; Bonsignori M; Sealy RE; Blanchard JL; Hurwitz JL Vaccine; 2005 Nov; 23(46-47):5306-20. PubMed ID: 16095768 [TBL] [Abstract][Full Text] [Related]
49. Fc receptor but not complement binding is important in antibody protection against HIV. Hessell AJ; Hangartner L; Hunter M; Havenith CE; Beurskens FJ; Bakker JM; Lanigan CM; Landucci G; Forthal DN; Parren PW; Marx PA; Burton DR Nature; 2007 Sep; 449(7158):101-4. PubMed ID: 17805298 [TBL] [Abstract][Full Text] [Related]
50. Elicitation of simian immunodeficiency virus-specific cytotoxic T lymphocytes in mucosal compartments of rhesus monkeys by systemic vaccination. Baig J; Levy DB; McKay PF; Schmitz JE; Santra S; Subbramanian RA; Kuroda MJ; Lifton MA; Gorgone DA; Wyatt LS; Moss B; Huang Y; Chakrabarti BK; Xu L; Kong WP; Yang ZY; Mascola JR; Nabel GJ; Carville A; Lackner AA; Veazey RS; Letvin NL J Virol; 2002 Nov; 76(22):11484-90. PubMed ID: 12388710 [TBL] [Abstract][Full Text] [Related]
51. Immune responses but no protection against SHIV by gene-gun delivery of HIV-1 DNA followed by recombinant subunit protein boosts. Putkonen P; Quesada-Rolander M; Leandersson AC; Schwartz S; Thorstensson R; Okuda K; Wahren B; Hinkula J Virology; 1998 Oct; 250(2):293-301. PubMed ID: 9792840 [TBL] [Abstract][Full Text] [Related]
52. Neutralization sensitivity of a simian-human immunodeficiency virus (SHIV-HXBc2P 3.2N) isolated from an infected rhesus macaque with neurological disease. Song B; Cayabyab M; Phan N; Wang L; Axthelm MK; Letvin NL; Sodroski JG Virology; 2004 Apr; 322(1):168-81. PubMed ID: 15063126 [TBL] [Abstract][Full Text] [Related]
53. Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heterologous HIV-1 infection. Derby NR; Kraft Z; Kan E; Crooks ET; Barnett SW; Srivastava IK; Binley JM; Stamatatos L J Virol; 2006 Sep; 80(17):8745-62. PubMed ID: 16912322 [TBL] [Abstract][Full Text] [Related]
54. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Barouch DH; Kunstman J; Kuroda MJ; Schmitz JE; Santra S; Peyerl FW; Krivulka GR; Beaudry K; Lifton MA; Gorgone DA; Montefiori DC; Lewis MG; Wolinsky SM; Letvin NL Nature; 2002 Jan; 415(6869):335-9. PubMed ID: 11797012 [TBL] [Abstract][Full Text] [Related]
55. Efficacy of DNA and fowlpox virus priming/boosting vaccines for simian/human immunodeficiency virus. Dale CJ; De Rose R; Stratov I; Chea S; Montefiori DC; Thomson S; Ramshaw IA; Coupar BE; Boyle DB; Law M; Kent SJ J Virol; 2004 Dec; 78(24):13819-28. PubMed ID: 15564490 [TBL] [Abstract][Full Text] [Related]
56. Humoral immunity to HIV, SIV, and SHIV. Haigwood NL; Zolla-Pazner S AIDS; 1998; 12 Suppl A():S121-32. PubMed ID: 9632993 [No Abstract] [Full Text] [Related]
57. Biphasic CD8+ T-Cell Defense in Simian Immunodeficiency Virus Control by Acute-Phase Passive Neutralizing Antibody Immunization. Iseda S; Takahashi N; Poplimont H; Nomura T; Seki S; Nakane T; Nakamura M; Shi S; Ishii H; Furukawa S; Harada S; Naruse TK; Kimura A; Matano T; Yamamoto H J Virol; 2016 Jul; 90(14):6276-6290. PubMed ID: 27122584 [TBL] [Abstract][Full Text] [Related]
58. Cytotoxic T lymphocyte and helper T cell responses following HIV polynucleotide vaccination. Shiver JW; Perry HC; Davies ME; Freed DC; Liu MA Ann N Y Acad Sci; 1995 Nov; 772():198-208. PubMed ID: 8546393 [TBL] [Abstract][Full Text] [Related]
59. Enhancement of mucosal immune responses by chimeric influenza HA/SHIV virus-like particles. Guo L; Lu X; Kang SM; Chen C; Compans RW; Yao Q Virology; 2003 Sep; 313(2):502-13. PubMed ID: 12954217 [TBL] [Abstract][Full Text] [Related]
60. Superior Efficacy of a Human Immunodeficiency Virus Vaccine Combined with Antiretroviral Prevention in Simian-Human Immunodeficiency Virus-Challenged Nonhuman Primates. Le Grand R; Dereuddre-Bosquet N; Dispinseri S; Gosse L; Desjardins D; Shen X; Tolazzi M; Ochsenbauer C; Saidi H; Tomaras G; Prague M; Barnett SW; Thiebaut R; Cope A; Scarlatti G; Shattock RJ J Virol; 2016 Jun; 90(11):5315-5328. PubMed ID: 27009957 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]